Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

Minghui Pharmaceutical Achieves First Dosing Milestone in Phase I Studies for ADC Candidates

Fineline Cube Jun 21, 2023

China-based biotech Minghui Pharmaceutical Inc. has reported that the first dosing has been completed in...

Company Deals

Xiamen ITG Group and Fosun Health Collaborate on Big Health Industry Fund and Medical Device Commercialization

Fineline Cube Jun 21, 2023

China-based Xiamen ITG Group Co., Ltd. (SHA: 600755) and Shanghai Fosun Health Technology (Group) Co.,...

Company Medical Device

Australian Scleral Lens Epicon A Approved by China’s NMPA as 10th Novel Product

Fineline Cube Jun 21, 2023

Ruitai Bio’s Epicon A, a scleral lens product from Australia, has been approved by the...

Company Drug

CDE Considers Breakthrough Therapy Designation for Beijing Mabworks’ MIL162 and Amgen’s AMG 890

Fineline Cube Jun 21, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Beijing Mabworks Biotech Co., Ltd’s...

Company Drug

Fujian Cosunter Pharmaceutical’s COVID-19 Drug GST-HG171 Meets Primary Endpoint in Phase II/III Study

Fineline Cube Jun 21, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the pivotal Phase II/III...

Company Drug

Boehringer Ingelheim’s Spevigo on Track for Priority Review for GPP Flare Prevention in China

Fineline Cube Jun 21, 2023

Germany-based Boehringer Ingelheim’s (BI) interleukin-36 receptor (IL-36R)-targeted orphan drug, Spevigo (spesolimab), in subcutaneous injection form,...

Company Drug

Bio-Thera Solutions’ PD-1 Inhibitor BAT1308 Approved for Cervical Cancer Clinical Trials in China

Fineline Cube Jun 21, 2023

Bio-Thera Solutions Ltd (SHA: 688177) has announced that its programmed death-1 (PD-1) inhibitor, BAT1308, has...

Company

Pfizer to Establish Smart Medical Innovation Center in Hangzhou’s Qiantang District

Fineline Cube Jun 20, 2023

US pharmaceutical giant Pfizer (NSE: PFIZER) has announced a plan to establish a smart medical...

Company Legal / IP

Medivir AB Receives Chinese Patent Approval for Liver Cancer Treatment Fostroxacitabine Bralpamide

Fineline Cube Jun 20, 2023

Sweden-based Medivir AB (FRA: MVR0) has announced the approval of a patent in China for...

Company Deals

Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform

Fineline Cube Jun 20, 2023

Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry...

Company Deals

Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics

Fineline Cube Jun 20, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has...

Company

Merck Appoints Marc Horn as China Unit President, Succeeding Allan Gabor

Fineline Cube Jun 20, 2023

Germany-based Merck (NYSE: MRK) has announced the appointment of Marc Horn as its China unit...

Company Drug

Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China

Fineline Cube Jun 20, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has officially commercialized its biosimilar version of AbbVie’s (NYSE:...

Company Drug

Grand Pharmaceutical Initiates Phase II STARBURST Study for TLX250-CDx in Indication Expansion

Fineline Cube Jun 20, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...

Company Deals

Novlead Biotech Secures RMB 100 Million in Series B+ Financing for Nitric Oxide Therapy Innovations

Fineline Cube Jun 20, 2023

Novlead Biotech, a specialist in nitric oxide gas detection and treatment based in Nanjing, has...

Company Deals

Guangdong Zhongsheng Pharmaceutical Plans to Raise RMB 600 Million via Private Placement

Fineline Cube Jun 20, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) is poised to raise RMB 600 million...

Company Drug

Shanghai Pharmaceuticals’ SPH3127 for Hypertension Gets MNPA Review Acceptance

Fineline Cube Jun 20, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...

Company Deals

United Imaging Healthcare Acquires Stake in Apactron for High-End Particle Therapy Technology

Fineline Cube Jun 20, 2023

Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million...

Company Deals

Sequanta Technologies Partners with DarkJade Sciences to Establish Organoid Bank and Glioma Project

Fineline Cube Jun 20, 2023

Sequanta Technologies, a leading multi-omics research and clinical service provider based in Shanghai, has announced...

Company Deals R&D

Insilico Medicine Partners with ShanghaiTech University for Tumor Drug R&D Advancement

Fineline Cube Jun 20, 2023

China-based AI-powered drug discovery firm Insilico Medicine has struck a partnership with ShanghaiTech University’s iHuman...

Posts pagination

1 … 539 540 541 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.